Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial.

MLA

Westhovens, René, et al. “Filgotinib in Combination with Methotrexate or as Monotherapy versus Methotrexate Monotherapy in Patients with Active Rheumatoid Arthritis and Limited or No Prior Exposure to Methotrexate: The Phase 3, Randomised Controlled FINCH 3 Trial.” Annals of the Rheumatic Diseases, vol. 80, no. 6, June 2021, pp. 727–38. EBSCOhost, https://doi.org/10.1136/annrheumdis-2020-219213.

APA

Westhovens, R., Rigby, W. F. C., van der Heijde, D., Ching, D. W. T., Stohl, W., Kay, J., Chopra, A., Bartok, B., Matzkies, F., Zhaoyu Yin, Ying Guo, Tasset, C., Sundy, J. S., Jahreis, A., Mozaffarian, N., Messina, O. D., Landewé, R. B. M., Tatsuya Atsumi, Burmester, G. R., & Yin, Z. (2021). Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Annals of the Rheumatic Diseases, 80(6), 727–738. https://doi.org/10.1136/annrheumdis-2020-219213

Chicago

Westhovens, René, William F. C. Rigby, Désirée van der Heijde, Daniel W. T. Ching, William Stohl, Jonathan Kay, Arvind Chopra, et al. 2021. “Filgotinib in Combination with Methotrexate or as Monotherapy versus Methotrexate Monotherapy in Patients with Active Rheumatoid Arthritis and Limited or No Prior Exposure to Methotrexate: The Phase 3, Randomised Controlled FINCH 3 Trial.” Annals of the Rheumatic Diseases 80 (6): 727–38. doi:10.1136/annrheumdis-2020-219213.